National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Rivaroxaban (Xarelto®) low dose for prevention of recurrent venous thromboembolism

Rivaroxaban 10mg daily for the prevention of recurrent venous thromboembolism in patients who have completed at least 6 months anticoagulation therapy for DVT or PE.

NCPE Assessment Process Complete
Rapid review received 20/11/2017
Rapid review completed 21/11/2017
Rapid Review outcome Full pharmacoeconomic assessment recommended

A full pharmacoeconomic evaluation is not required as rivaroxaban 10mg is reimbursable under the Community Drug Schemes